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ABSTRACT
Introduction: Acute lymphoblastic leukaemia 
(ALL) is a heterogeneous group of lymphoid 
neoplasm resulting from the proliferation of 
malignant lymphoid cells. We aimed to study the 
outcome of adult patients with ALL receiving the 
Medical Research Council UKALL XII protocol.
Methods : This was a retrospective study 
conducted at Aga Khan University Hospital from 
January 2001 to December 2008. The medical 
records of all adult patients were reviewed 
and analysed for clinical, morphological and 
immunological features at presentation and 
impact on treatment outcomes. Multivariate 
analysis and survival studies were performed 
using Kaplan-Meier statistics.
Results: The total number of patients was 54, 
with a male to female ratio of 3.4:1 and a median 
age of 28 years. Common presenting symptoms 
were fever (n is 49) and bleeding (n is 14). 38 
patients had haemoglobin less than 10 gms/dl, 21 
had white blood cell (WBC) count of 50 × 10E9/L 
or more, and 35 had lactate dehyrogenase 
more than 1,000 IU. Morphologically, FAB-L2 
was the commonest subtype, with 38 patients 
with B-ALL and eight with T-ALL. Multivariate 
analysis showed that age above 30 years, male 
gender, WBC count above 50 × 10E9/L and 
T-ALL subtype were independent risk factors for 
poor survival. 46 (85 percent) patients achieved 
complete remission. The median survival was 
12.3 months. At the end of five years, 16 patients 
were alive, two were alive with disease and 14 
were in complete remission.
Conclusion: Overall survival and relapse rates 
in our study were comparable to those reported 
internationally.
Keywords: acute lymphoblastic leukaemia, 
adults, MRC UKALL XII protocol, Philadelphia 
chromosome, treatment outcome
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INTRODUCTION
Acute lymphoblastic leukaemia (ALL) is a heterogeneous 
group of lymphoid neoplasm resulting from monoclonal 
proliferation of malignant lymphoid cells in the blood, 
bone marrow and other organs.(1) Currently, due to 
intensive chemotherapy regimens, the outcome of adult 
ALL has improved markedly. The complete response 
rates now are more than 80%(2) and the long-term 
survival rate is 30%–45%.(3) In the past five decades, the 
outcome of childhood ALL has evolved from a median 
survival of two months at the time of diagnosis(4) to a 
long-term survival rate of 80%.(5) The better results seen 
among the childhood population as compared to adults 
with ALL have been attributed to a number of prognostic 
factors.
 White blood cell (WBC) count at presentation is an 
important risk factor reported in almost every study done 
on adult ALL.(6) The widely used cut-offs for B and T 
lineage are 30 × 109/L and 100 × 109/L, respectively.(7) 
The presence of a Philadelphia chromosome is the most 
important cytogenetic abnormality in ALL. It is present 
in 20%–30% of patients and indicates a grave prognosis 
with standard chemotherapy.(8) Male gender has been 
reported to be an independent prognostic risk factor, 
with male patients faring worse than female patients, the 
most probable reason being relapse at sanctuary sites, 
e.g. the testes.(9) Finally, response to initial treatment has 
been regarded as the most significant risk factor, as data 
suggests that the inability to achieve clearance at Day 10 
correlates with a worse outcome. However, this data has 
mainly been published in childhood ALL series.(10)     
 There are a number of studies on the outcomes of 
adults diagnosed with ALL in the literature. However, 
such information is sparse from our part of the world. 
This study was designed to describe the survival 
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outcomes of adult patients with ALL in the Pakistani 
population. 
METHODS
This was a retrospective study conducted at Aga 
Khan University Hospital in adult patients aged > 15 
years between January 2001 and December 2008. The 
medical records of all patients (using the International 
Classification of Disease 9th edition) (ICD-9), were 
reviewed through an in-house questionnaire. Consecutive 
patients diagnosed as ALL subtype L1 and L2 according 
to the French-American-British (FAB) classification were 
included in the study, while those diagnosed as ALL L3 
were excluded from the study. Data of all included patients 
was analysed with respect to their clinical presentation, 
morphological and immunopathological features and 
treatment outcomes. 
 Flow cytometry was performed on FACScan (Becton 
Dickinson, Miami Lakes, FL, USA). The following 
monoclonal antibodies were used: T-lineage-associated 
antigens CD3, CD5, CD7; B-lineage antigens CD19, 
CD20, CD79a, CD22; and antigens TdT and CD10. 
Conventional cytogenetic analysis and BCR-ABL 
translocation by fluorescent in situ hybridisation were 
performed in all patients. Pre-treatment investigations 
included complete blood count, blood chemistry, including 
liver and renal function tests, lactate dehyrogenase (LDH), 
uric acid and serum electrolytes. 
 Patients were treated using the Medical Research 
Council United Kingdom ALL (MRC UKALL) XII 
protocol, which consisted of induction therapy divided 
in two phases. Phase 1 consisted of the following: 
daunorubicin 60 mg/m2 (intravenous [IV]) on Days 
1, 8, 15 and 22; vincristine 1.4 mg/m2 (IV) on Days 
1, 8, 15 and 22; L-asparaginase 10,000 IU (IV or 
intramuscular) on Days 17–28; prednisone 60 mg/m2 
(oral) in divided doses on Days 1–28; and methotrexate 
12.5 mg (intrathecal) on Day 15. Patients then went on to 
Phase 2 of induction, which consisted of the following: 
cyclophosphamide 650 mg/m2 (IV) on Days 1, 15 and 
29; cytarabine 75 mg/m2 (IV) on Days 1–4, 8–11, 15–18 
and 22–25; 6-mercaptopurine 60 mg/m2 (oral) on Days 
1–28; and methotrexate 12.5 mg (intrathecal). Patients 
were evaluated for response at the end of each of the 
two phases of induction. Those who achieved complete 
remission proceeded to intensification and post-
remission consolidation. 
 Patients undergoing intensification therapy 
received three cycles of high-dose methotrexate 3 g/m2 
administered intravenously on Days 1, 8 and 22, followed 
by L-asparaginase 10,000 IU on Days 2, 9 and 23, and 
standard leucovorin rescue. In the consolidation phase, 
patients received central nervous system prophylaxis 
2,400 cGy cranial irradiation and intrathecal cytarabine 
50 mg weekly for a period of four weeks. In addition, 
intrathecal cytarabine 50 mg was administered on four 
occasions three months apart during the maintenance 
therapy. Maintenance therapy consisted of vincristine 1.4 
mg/m2 (IV) every three months, prednisone 60 mg/m2 
(oral) for five days every three months, 6-mercaptopurine 
75 mg/m2 (oral) a day, and methotrexate 20 mg/m2 (oral 
or IV) once a week. The therapy was continued for a total 
of 2.5 years from the start of intensification therapy.(11)
 Data was collected on a computerised database 
and analysed using the Statistical Package for the 
Social Sciences version 16.0.1 (SPSS Inc, Chicago, IL, 
USA). Data was presented as mean/median values and 
percentages. Kaplan-Meier curves were used to calculate 
survival outcomes and Cox-proportional hazard model 
for multivariate analysis.
Table I. Laboratory parameters (n = 54).
Parameter No. (%) Mean ± SD (range)
Haemoglobin < 10 gm/dl 14 (28.6)   8.6 ± 2 (4.5–14.2)
Total leucocyte count ≥ 50 × 109/L 21 (43.8)   95 ± 140 (0.9–720)
Platelets ≤ 10 × 109/L  3 (6.3)  44.5 ± 38  (4–245)
Lactate dehydrogenase ≥ 1,000 IU/L 35 (77) 5,173 ± 9,464 (3,554–3,768)
Uric acid ≥ 8 mg/dl  6 (17.9)   6.3 ± 3 (2–16)
Table II.  Leukaemia characteristics (n = 54).
Characteristic No. (%)
Morphology
 L1  4 (7.4)
 L2 50 (92.5)
Immunophenotyping* 
 B-ALL 38 (82.6)
 T-ALL  8 (17.4)
Cytogenetics 
 Normal  27 (50.0)
 t9;22  8 (15.0)
 Complex 11 (20.3)
* Data is missing for 8 patients.
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RESULTS
During the study period, 54 (42 male and 12 female) 
patients were admitted with a diagnosis of ALL. The 
median age of the patients was 28 (range 16–53) 
years, of which 28 (52%) were ≤ 30 years of age. 
The common presenting symptoms were fever (n = 
49, 82%) and bleeding (n = 14, 25.5%). 42 (79.0%) 
patients had anaemia, and 35.2% and 18.5% of patients 
had enlarged lymph nodes and liver, respectively. Poor 
prognostic factors other than male gender, according 
to the Luken’s criteria,(12) were white cell count ≥ 50 
× 109/L (n = 21, 43.8%). 63.0% (n = 34) of patients 
had splenomegaly, 77.0% (n = 35) had LDH ≥ 1,000 
IU/L and 92.5% (n = 50) were diagnosed with L2 
FAB subtype. Immunophenotyping by flow cytometry 
revealed 38 patients with B-ALL phenotype; in these 
patients, the mean WBC count was 69 ± 92.7 (range 
0.9–450) × 109/L. T-ALL was present in eight patients 
and their mean WBC count was 82 ± 107 (range 2.4–
331) × 109/L. Normal chromosomal analysis was present 
in 27 (50.0%) patients, while 20.3% had complex 
cytogenetic abnormalities. Philadelphia chromosome 
positivity was seen in eight patients. One patient 
each had hyperdiploidy and polysomy 9 cytogenetic 
abnormalities. Details of the laboratory parameters are 
shown in Tables I and II.  
 All 54 patients received treatment and were 
evaluated for response. Overall, 46 (85.0%) patients 
went into complete remission. The median time taken to 
achieve complete remission was 30 (range 20–43) days. 
Four patients died during induction chemotherapy; the 
primary cause of death was tumour lysis syndrome (n 
= 2) and primary induction failure due to progressive 
disease (n = 2). Four patients discontinued treatment 
after receiving a few days of induction therapy and 
moved to other hospitals due to financial reasons.
 After a median follow-up period of 18.7 months, 
24 (44.4%) patients suffered a relapse with systemic 
disease and died, whereas 16 (30.0%) were alive. Of 
these, two were alive with disease and 14 (26.0%) were 
in complete remission at the end of the study period (Fig. 
1). Multivariate analysis showed that age > 30 years, 
male gender, WBC count ≥ 50 × 109/L, haemoglobin < 
10 gm/dl and complex cytogenetics were independent 
risk factors for poor outcome (Fig. 2). The median 
survival was 12.7 months and disease-free survival was 
6.2 months (Figs. 3 & 4).
DISCUSSION
In 2008, 44,000 new cases of leukaemia were diagnosed 
in the West, out of which 42% were acute leukaemia; of 
these, childhood ALL made up 72%.(13)  The incidence 
of childhood ALL in Pakistan was 32%.(14) Many reports 
have suggested that adolescents and young adults with 
ALL have a better outcome when they are treated with 
paediatric protocols, with survival ranging from 65% 
to 69%.(15) However, the duration of remission has 
been disappointingly short.(16) We present a seven-year 
analysis in the adult population based on 54 patients 
diagnosed with ALL.
 This retrospective analysis focused on three 
important prognostic factors that influence the survival 
of ALL, including age > 30 years, male gender 
and increased WBC count, as well as two rather 
new prognostic factors – immunophenotyping and 
cytogenetic analysis. These risk factors have already 
been established as indicators of poor outcome,(17) and 
our study confirms their relevance to our population as 
well. Age is probably the most important prognostic 
factor. Multiple groups have quoted that overall survival 
continuously decreases with increasing age, from 34% 
to 57% for patients < 30 years to 15% to 17% for those 
> 50 years.(18) The median age of our patients was 24 
years. However, the median survival of patients aged 
> 30 years was 6.8 months, thus reflecting the survival 
disadvantage.
 WBC cell count at diagnosis (≥ 50 × 109/L) 
is associated with an increased risk of relapse.(19) 
Approximately 33% (n = 18) of our patients with 
B-ALL had a WBC count > 30 × 109/L, whereas 3.7% of 
those with T-ALL had a WBC count > 1009L. Although 
85% of patients achieved complete remission during 
induction, 44% relapsed during or after the completion 
of treatment. Furthermore, increased WBC count is 
also associated with a risk of complications during 
induction,(20) as seen in 11% of our patients. Gender 
is known to be an independent predictive factor for 
complete remission,(21) and there was a definite male 
preponderance in our study, similar to that reported in 
Fig. 1 Outcome of patients with acute lymphoblastic leukaemia
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Fig. 2 Correlation of prognostic factors: (a) age; (b) gender; (c) immunophenotype; and (d) cytogenetics with outcome.
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the Western literature.(22) Male gender has been reported 
to have inferior outcomes,(23) which was also the case in 
our study.
 Complete immunologic characterisation at 
diagnosis is required to identify subtypes with different 
presentations and prognosis. Immunophenotyping 
by flow cytometry has long been considered a critical 
part of diagnostic evaluation in patients with ALL. 
Many groups have confirmed the superior outcome of 
T-lineage ALL as compared to B-lineage ALL.(24) This 
is in sharp contrast to our study, where patients in the 
B-ALL subgroup did fairly well. This could be due to 
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Fig. 4 Kaplan-Meier plots of disease-free survival.
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Fig. 3 Kaplan-Meier plots of overall survival.
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the higher number of patients with B-ALL as compared 
to T-ALL. Furthermore, only two patients with T-ALL 
had a WBC count > 100 × 109/L, thereby improving the 
overall outcome.
 Philadelphia chromosome positivity, with an overall 
incidence of 20%–40% in adults, has an extremely 
poor prognosis.(25) Its incidence rises to 50% in patients 
aged ≥ 50 years.(26) Eight patients in our study had 9;22 
translocation (Philadelphia chromosome), out which one 
was alive till the last follow-up. The debate on whether 
young adults or adolescents should be treated with 
paediatric protocols remains.(27) The overall and median 
survival rates are not inevitably lower when these 
patients are treated with adult protocols, as shown in our 
study. However, when compared with children below ten 
years of age, the outcomes are poorer, mainly due to the 
increased risk of relapse.  
 We conclude that three risk factors that still influence 
survival outcomes in adult lymphoblastic leukaemia are 
age > 30 years, male gender and WBC count > 50 × 
109/L. Immnophenotyping and cytogenetic analysis are 
required for complete characterisation and prognosis. 
These five factors would help physicians to stratify 
patients into low- and high-risk groups. The median 
survival in our study was 12.7 months and disease-free 
survival was 6.2 months.
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